WASHINGTON – A large group of U.S. states accused key players in the generic drug industry of a broad price-fixing conspiracy, moving on Tuesday to widen an earlier lawsuit to add many more drug makers and medicines in an action that sent some company shares tumbling.
The lawsuit, brought by the attorneys general of 45 states and the District of Columbia, accused 18 companies and subsidiaries and named 15 medicines. It also targeted two individual executives: Rajiv Malik, president and executive director of Mylan NV; and Satish Mehta, CEO and managing director of India’s Emcure Pharmaceuticals.
Shares of Pennsylvania-based Mylan, also named as a defendant, fell more than 6 percent after the news.
The states said the drug makers and executives conspired to fix prices and split up the market for generic drugs, which are intended to deliver to consumers lower prices than their brand-named counterparts.
“It is our belief that price-fixing is systematic, it is pervasive, and that a culture of collusion exists in the industry,” Connecticut Attorney General George Jepsen, who is leading the case, told a news conference in Hartford.
Mylan said in a statement it had found no evidence of price-fixing by the company or any of its employees, and vowed to defend itself vigorously. Malik, the company’s second-ranking official, has received more than $50 million in compensation over the past three years, last year making more than CEO Heather Bresch.
“Mylan has deep faith in the integrity of its president, Rajiv Malik, and stands behind him fully,” the company said.
Soaring drug prices from both branded and generic drug manufacturers have sparked outrage and investigations in the United States. President Donald Trump this year accused pharmaceutical companies of “getting away with murder” with their drug pricing.
Executives like Mylan’s Bresch and former Turing Pharmaceuticals CEO Martin Shkreli have been called in front of Congress to defend the cost of their products.
The original complaint, filed in December, targeted Emcure Pharmaceuticals’ unit Heritage Pharmaceuticals Inc., Aurobindo Pharma USA Inc., Citron Pharma LLC, Mayne Pharma USA Inc., Mylan and Teva Pharmaceuticals USA Inc.
The states are pressing a new complaint that would add Novartis AG’s unit Sandoz, India-based Sun Pharmaceutical Industries Ltd., Endo International PLC’s unit Par Pharmaceutical, Dr. Reddy’s Laboratories, Apotex Corp., Glenmark Generics Ltd., Lannett Company Inc., Alkem Laboratories Ltd.’s unit Ascend Laboratories and Cadila Healthcare Ltd.’s unit Zydus Pharmaceuticals Inc.
Jepsen said the investigation is continuing, and that claims would likely be brought against even more companies, and possibly executives, in the future.
The news hurt shares of companies named in the expanded suit that are traded in the United States, pulling Lannett down as much as 7 percent. Shares of Endo pared nearly 8 percent off a more than 12 percent gain on the day, which followed the company’s earlier estimate it would earn more than expected.
Teva spokeswoman Denise Bradley said the company denied the allegations. Endo spokeswoman Heather Lubeski said the company would vigorously defend itself against the claims. Other companies did not immediately respond to requests for comment.
The expansion of the suit requires the court’s permission.
The original lawsuit centered on just two medicines: a delayed-release version of a common antibiotic, doxycycline hyclate; and glyburide, an older drug used to treat diabetes.
The price of doxycycline rose from $20 for 500 tablets to $1,849 between October 2013 and May 2014, according to U.S. Sen. Amy Klobuchar, a Minnesota Democrat who had been pressing for action on high drug prices.
The amended complaint would expand the number of drugs to include glipizide-metformin and glyburide-metformin, which are among the most commonly used diabetes treatments.
Others include: acetazolamide, which is used to treat glaucoma and epilepsy; the antibiotic doxycycline monohydrate; the blood pressure medicine fosinopril; the anti-anxiety medicine meprobamate; and the calcium channel blocking agent nimodipine.
The U.S. Justice Department is conducting a parallel criminal investigation. On Friday, the department asked the Pennsylvania court presiding over the lawsuit to put the lawsuit’s discovery process on hold, saying it could interfere with the criminal probe.
Connecticut Assistant Attorney General Joseph Nielsen said on Tuesday the states would likely oppose that request, which could slow the lawsuit.
In a time of both misinformation and too much information, quality journalism is more crucial than ever.
By subscribing, you can help us get the story right.